Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.22, Iss.8, 2012-08, pp. : 971-976

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557?

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 8, 2012-08 ,pp. : 965-970

Informa Healthcare

Access to resources Recommend Favorite

Novel 1,5-naphthyridine PI3Kδ inhibitors, an evaluation of WO2011075628

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 11, 2011-11 ,pp. : 1805-1810

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 5, 2014-05 ,pp. : 603-607

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 6, 2014-06 ,pp. : 719-722

Informa Healthcare

Access to resources Recommend Favorite

Selective PI3Kδ inhibitors, a review of the patent literature

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 11, 2011-11 ,pp. : 1773-1790

Informa Healthcare

Access to resources Recommend Favorite